About OncoDNA Group
We are a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases.
Our mission : Improving patients' health through precision care
OncoDNA’s ultimate mission is to improve patients’ outcomes by empowering physicians, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.
Based on years of experience and Research and Development, we have been able to develop cutting-edge solutions. Our unique portfolio combines 3 pillars: cancer biomarker tests, genomic services in oncology and data interpretation tools.
Reliability
Quality
Innovation
Rapidity
Our history
OncoDNA, was born in 2012 from the idea of making precision medicine a reality in oncology. Combined with other technologies, Next-Generation Sequencing had the power to revolutionize the diagnosis and treatment of cancers and rare diseases and bring the right treatment for the right patient at the right time.
In just a decade, we have grown into a renown company that drives innovation in research, accelerates drug development and has helped thousands of patients globally. Today, OncoDNA comprises two entities – BioSequence and IntegraGen – and employs more than 120 employees in 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.
« When I founded OncoDNA, I wished to bring the best of care to cancer patients and give them new hope. Today OncoDNA is the European champion in precision oncology. I am proud to be working with passionate teams who strive to foster innovation and advance patient care. »
Jean-Pol DETIFFE, Founder of OncoDNA
Our leadership
Driving innovation in molecular profiling
Better understanding the behavior and molecular characteristics of a disease is key to improve patient journey and clinical outcome. At OncoDNA, we are specializing in the genomics and theranostics of cancer and genetic diseases. This enables us not only to bring the molecular insights that researchers, biopharma companies and clinicians need, but also to facilitate the analysis and clinical interpretation of those complex data.
We strongly believe that empowering our employees and partners is key to stay ahead of the science. The field of genomics is advancing fast. Thanks to our flexibility, entrepreneurial mindset and highly competent teams, we have been able to develop a complete portfolio of genomic services, biomarker tests and bioinformatics solutions to support the translation of precision medicine from bench to bedside. Over the years, our solutions have helped deliver breakthrough, accelerate drug development, and bring therapeutic innovation into routine care.
OncoDNA has the unique potential to address the needs of the entire value chain, from translational research and drug development to patient treatment and monitoring. Our integrated portfolio and our highly experienced teams is what makes us different. We not only provide the best of genomic services and software solutions, we also deliver administrative, logistics and scientific support from A to Z.
Foundation
Our impact
Our solutions have an impact on patients’ cancer journey the world over. We are proud to say that our biomarker tests and clinical decision support have contributed to the treatment of over 100,000 patients. It is motivating to see how they have improved their quality of life and clinical outcomes.
Clinical Resources
MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice
Gosselies – Belgium, October 29, 2024 MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced...
The NHS South East Genomic Medicine Service transitions to the OncoDEEP Kit a Solid Tumour Panel that can transform oncology patients’ lives as a result of timely comprehensive genomic testing.
The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically...
Validation of the OncoDEEP® Kit comprehensive genomic panel on the MGI platform
Introduction : This study aims to compare tumour characterization using the OncoDEEP® Kit end-to-end solution with an MGI sequencer as an alternative to Illumina technology. The validation results demonstrate that the MGI platform, by generating...
